Trial Profile

First-in-man trial of CAP 7.1 in patients with heavily treated solid tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etoposide-toniribate (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors CellAct Pharma

Most Recent Events

07 Jun 2016 Results assessing pooled population pharmacokinetics from this and other Phase II trial (n=39) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
03 Jun 2016 According to a CellAct Pharma media release, pooled population pharmacokinetic data from this and a phase II study (see profile 222582) were presented at the 52nd Annual Meeting of the American Society for Clinical Oncology (ASCO).
03 Jun 2016 Results of pooled population pharmacokinetic data from this and a phase II study (see profile 222582) published in a CellAct Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com